JP2010527981A5 - - Google Patents

Download PDF

Info

Publication number
JP2010527981A5
JP2010527981A5 JP2010508909A JP2010508909A JP2010527981A5 JP 2010527981 A5 JP2010527981 A5 JP 2010527981A5 JP 2010508909 A JP2010508909 A JP 2010508909A JP 2010508909 A JP2010508909 A JP 2010508909A JP 2010527981 A5 JP2010527981 A5 JP 2010527981A5
Authority
JP
Japan
Prior art keywords
week
chk
administered
treatment
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010508909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2008/050372 external-priority patent/WO2008146035A1/en
Publication of JP2010527981A publication Critical patent/JP2010527981A/ja
Publication of JP2010527981A5 publication Critical patent/JP2010527981A5/ja
Pending legal-status Critical Current

Links

JP2010508909A 2007-05-25 2008-05-23 癌処置用のchk阻害剤およびparp阻害剤の組み合わせ剤 Pending JP2010527981A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94020307P 2007-05-25 2007-05-25
PCT/GB2008/050372 WO2008146035A1 (en) 2007-05-25 2008-05-23 Combination of chk and parp inhibitors for the treatment of cancers

Publications (2)

Publication Number Publication Date
JP2010527981A JP2010527981A (ja) 2010-08-19
JP2010527981A5 true JP2010527981A5 (enExample) 2011-06-30

Family

ID=39672970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010508909A Pending JP2010527981A (ja) 2007-05-25 2008-05-23 癌処置用のchk阻害剤およびparp阻害剤の組み合わせ剤

Country Status (11)

Country Link
US (1) US20100249112A1 (enExample)
EP (1) EP2167086A1 (enExample)
JP (1) JP2010527981A (enExample)
KR (1) KR20100020981A (enExample)
CN (1) CN101743003A (enExample)
AU (1) AU2008256562A1 (enExample)
BR (1) BRPI0811059A2 (enExample)
CA (1) CA2687786A1 (enExample)
MX (1) MX2009012705A (enExample)
RU (1) RU2009147819A (enExample)
WO (1) WO2008146035A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081778A1 (en) * 2009-01-17 2010-07-22 Universität Zürich Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
WO2012014221A1 (en) 2010-07-27 2012-02-02 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
MX2015006780A (es) 2012-12-31 2015-08-06 Cadila Healthcare Ltd Derivados de ftalazin-1-(2h)-ona sustituida.
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
MX2019012176A (es) 2017-04-10 2020-02-19 Sierra Oncology Inc Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
CA3095709A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN120441567A (zh) 2020-04-07 2025-08-08 Crt先锋基金有限公司 Chk1抑制剂的合成方法
CN112375070B (zh) * 2020-06-29 2023-03-28 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
WO2022000946A1 (zh) * 2020-06-29 2022-01-06 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
SG150548A1 (en) * 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
JP2007517843A (ja) * 2004-01-05 2007-07-05 アストラゼネカ アクチボラグ Chk1阻害剤であるチオフェン誘導体
WO2006078503A2 (en) * 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage

Similar Documents

Publication Publication Date Title
JP2024133475A5 (enExample)
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
JP2013507415A5 (enExample)
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
FI2694072T4 (fi) Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
JP2014515373A5 (enExample)
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
CL2018001371A1 (es) Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807)
NZ714963A (en) Compositions and methods for treating anemia
JP2014528901A5 (enExample)
JP2012526850A5 (enExample)
JP2016529285A5 (enExample)
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2016516773A5 (enExample)
EP4520398A3 (en) Treatment of prostate cancer
UA104148C2 (ru) [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1h-индол-3-ил]-метанон как ингибитор триптазы тучных клеток
JP2020523354A5 (enExample)
JP2015535247A5 (enExample)
CL2024001530A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
JP2013544892A5 (enExample)
IL259512B1 (en) Combination for effective treatment of metastatic cancer in patients